|
|||||
|
|
| 抗肺纤维化药物研究进展 | |
| 引用本文： | 姜懋,孟婕. 抗肺纤维化药物研究进展[J]. 国际呼吸杂志, 2017, 37(18). DOI: 10.3760/cma.j.issn.1673-436X.2017.18.017 |
| 作者姓名： | 姜懋 孟婕 |
| 作者单位： | 中南大学湘雅医院呼吸内科(呼吸与危重症医学科)国家呼吸疾病临床医学研究中心核心单位,长沙,410008 |
| 基金项目： | 国家自然科学基金项目(81470255).National Natural Science Foundation of China |
| 摘 要： | 肺纤维化是严重危害人类健康的公共卫生问题,诊断后中位生存期仅为2～3年,目前已有的抗肺纤维化药物疗效甚微.随着肺纤维化发病机制的进展,多种潜在的抗肺纤维化药物靶点被发现.本文概述肺纤维化的流行病学情况、病因和发病机制,重点介绍作用于炎症、氧化应激、肺泡上皮细胞、肌成纤维细胞等靶点的抗肺纤维化药物的开发现状及展望. |
| 关 键 词： | 肺纤维化 抗肺纤维化药物 临床试验 |
Advances of drugs for pulmonary fibrosis |
|
| Jiang Mao,Meng Jie. Advances of drugs for pulmonary fibrosis[J]. International Journal of Respiration, 2017, 37(18). DOI: 10.3760/cma.j.issn.1673-436X.2017.18.017 | |
| Authors: | Jiang Mao Meng Jie |
| Abstract: | Pulmonary fibrosis is a serious public problem threatening people's health with a median survival time of 2 3 years after diagnosis.Currently,anti-fibrotic drugs have showed little effect.With the advances of mechanisms of pulmonary fibrosis,multiple potential anti-fibrotic targets have been developed.This review summarizes the epidemiology,etiology and pathogenesis of pulmonary fibrosis,and then emphasizes on the prospects of new anti-fibrotic drugs that mainly target inflammation,oxidative stress,alveolar epithelial cells and myofibroblasts. |
| Keywords: | Pulmonary fibrosis Anti-fibrotic drugs Clinical trials |
| 本文献已被 万方数据 等数据库收录！ | |